Inactivation of papain by antithrombin due to autolytic digestion: a model of serpin inactivation of cysteine proteinases.
Cross-class inhibition of cysteine proteinases by serpins differs from serpin inhibition of serine proteinases primarily in that no stable serpin-cysteine proteinase complex can be demonstrated. This difference in reaction mechanism was elucidated by studies of the inactivation of the cysteine proteinases, papain and cathepsin L, by the serpin antithrombin. The two proteinases were inactivated with second-order rate constants of (1.6+/-0.1)x10(3) and (8.6+/-0. 4)x10(2) M-1.s-1 respectively. An antithrombin to papain inactivation stoichiometry of approximately 3 indicated extensive cleavage of the inhibitor concurrent with enzyme inactivation, a behaviour verified by SDS/PAGE. N-terminal sequence analyses showed cleavage predominantly at the P2-P1 bond, but also at the P2'-P3' bond of antithrombin. The papain band in SDS/PAGE progressively disappeared on reaction of the enzyme with increasing amounts of antithrombin, but no band representing a stable antithrombin-papain complex appeared. SDS/PAGE with 125I-labelled papain showed that the disappearance of papain was caused by cleavage of the enzyme into small fragments. These results suggest a mechanism in which papain attacks a peptide bond in the reactive-bond loop of antithrombin adjacent to that involved in serine proteinase inhibition. The reaction proceeds, similarly to that between serpins and serine proteinases, to form an inactive acyl-intermediate complex, although with the substrate pathway dominating in the papain reaction. In this complex, papain is highly susceptible to proteolysis and is degraded by still active papain, which greatly decreases the lifetime of the complex and results in liberation of fragmented, inactive enzyme. This model may have relevance also for the inactivation of physiologically or pathologically important cysteine proteinases by serpins.
Björk
I
I
Department of Veterinary Medical Chemistry, Swedish University of Agricultural Sciences, Uppsala Biomedical Center, Box 575, SE-751 23 Uppsala, Sweden. Ingemar.Bjork@vmk.slu.se
Nordling
K
K
Raub-Segall
E
E
Hellman
U
U
Olson
S T
ST
D000991:Antithrombins / Q000302:isolation & purification / Q000494:pharmacology* / Q000502:physiology; D056668:Cathepsin L; D002403:Cathepsins / Q000037:antagonists & inhibitors; D003174:Complement C1 Inactivator Proteins / Q000494:pharmacology; D003546:Cysteine Endopeptidases / Q000378:metabolism*; D010450:Endopeptidases; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D007700:Kinetics; D008956:Models, Chemical; D010206:Papain / Q000037:antagonists & inhibitors* / Q000737:chemistry; D010449:Peptide Mapping; D017395:Plasminogen Activator Inhibitor 1 / Q000494:pharmacology; D015843:Serpins / Q000494:pharmacology*
D000991:Antithrombins; D003174:Complement C1 Inactivator Proteins; D017395:Plasminogen Activator Inhibitor 1; D015843:Serpins; D006493:Heparin; D002403:Cathepsins; D010450:Endopeptidases; D003546:Cysteine Endopeptidases; C534281:CTSL protein, human; D056668:Cathepsin L; D010206:Papain